IV Vitamin C + Chemotherapy for Bladder Cancer

Not currently recruiting at 2 trial locations
CT
Overseen ByClinical Trials Nurse Navigator
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: University of Kansas Medical Center
Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether adding high doses of vitamin C (ascorbic acid) to chemotherapy can more effectively combat bladder cancer. It targets individuals with muscle-invasive bladder cancer who cannot use the usual cisplatin chemotherapy due to health issues. Instead, they will receive a combination of vitamin C and other chemotherapy drugs, carboplatin and gemcitabine, to assess improvements in treatment outcomes. Individuals with bladder cancer who cannot receive cisplatin and have no major health problems might be suitable for this trial. As a Phase 1, Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking cancer treatment advancements.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, you cannot use other investigational agents while participating in this study.

Is there any evidence suggesting that this treatment is likely to be safe for humans?

Research shows that receiving vitamin C through an IV is generally safe. Studies have found that high doses administered this way are usually well-tolerated in various cancer treatments, with most people experiencing no serious side effects. In some studies, vitamin C was used alongside regular cancer treatments and remained safe.

Some research suggests that high doses of vitamin C can target cancer cells without harming normal cells. This is promising because it might mean the treatment is gentler on the body. However, safety can vary among individuals, so consulting a healthcare professional before joining a trial is important.12345

Why do researchers think this study treatment might be promising for bladder cancer?

Unlike the standard treatments for bladder cancer, which typically involve chemotherapy drugs like cisplatin or gemcitabine, this investigational approach involves high doses of vitamin C, known as ascorbic acid, delivered directly into the bloodstream. Researchers are excited because this delivery method allows for much higher concentrations of vitamin C, which may enhance the effectiveness of chemotherapy by acting as a pro-oxidant that selectively targets cancer cells. This approach is unique because it potentially boosts the cancer-fighting power of traditional treatments while minimizing damage to healthy cells.

What evidence suggests that IV Vitamin C could be an effective treatment for bladder cancer?

Research has shown that high-dose intravenous (IV) vitamin C may help fight cancer by attacking cancer cells, altering their genes, and strengthening the immune system. In previous studies, this treatment reduced tumor size in about one-third of bladder cancer patients before surgery. In this trial, participants will receive IV vitamin C as an experimental treatment. Some early evidence suggests that adding IV vitamin C to chemotherapy can enhance its effectiveness. These findings offer hope for patients unable to use standard treatments.12467

Who Is on the Research Team?

JT

John Taylor, MD MS

Principal Investigator

The University of Kansas

Are You a Good Fit for This Trial?

This trial is for adults with muscle invasive bladder cancer who can't have cisplatin-based chemotherapy. They must be in fair to good health, not pregnant or breastfeeding, and willing to use birth control. Smokers and those with certain medical conditions or treatments are excluded.

Inclusion Criteria

I am able to get out of my bed or chair and move around.
I agree to use specified birth control methods if I or my partner can become pregnant.
I cannot receive cisplatin and have muscle invasive bladder cancer.
See 1 more

Exclusion Criteria

Current or anticipated use of other investigational agents while participating in this study
I am not pregnant or breastfeeding.
You currently use tobacco products.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive IV Ascorbic Acid 25 grams infused 2 times a week for 4 weeks alongside gemcitabine/carboplatin chemotherapy

4 weeks
8 visits (in-person)

Post-treatment Evaluation

Post treatment specimen pathology results evaluated per the WHO TNM staging system

6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including quality of life assessments

6 weeks

Long-term Follow-up

Disease Free Survival Rate (DFS) monitored among participants

5 years

What Are the Treatments Tested in This Trial?

Interventions

  • Ascorbic Acid
Trial Overview The study tests if adding high-dose vitamin C (IVC) to the chemo drugs carboplatin and gemcitabine helps treat bladder cancer better than chemo alone. It's for patients who can't tolerate the usual cisplatin drug due to other health issues.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: IV Ascorbic AcidExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Kansas Medical Center

Lead Sponsor

Trials
527
Recruited
181,000+

National Center for Advancing Translational Sciences (NCATS)

Collaborator

Trials
394
Recruited
404,000+

Citations

Intravenously administered vitamin C as cancer therapyEarly clinical studies showed that high-dose vitamin C, given by intravenous and oral routes, may improve symptoms and prolong life in patients with ...
High-dose vitamin C: A promising anti-tumor agent, insight ...High-dose vitamin C exhibits selective anti-tumor effects, including pro-oxidative cytotoxicity, anti-cancer epigenetic regulation, and immune modulation.
New Study Aims to Improve Bladder Cancer Treatment ...Results from their phase I trial showed that this combination shrunk tumor size in up to one-third of patients before surgery. In addition, this ...
Study Results | NCT04046094 | Intravenous (IV) Vitamin C ...These trials gather additional information about a drug's safety, efficacy ... Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder ...
High-dose intravenous vitamin C, a promising multi-targeting ...Mounting evidence indicates that vitamin C has the potential to be a potent anti-cancer agent when administered intravenously and in high doses (high-dose IVC).
Clinical efficacy and safety of oral and intravenous vitamin ...Oral intake of vitamin C does not appear to have any effect in patients with malignancies. Data are heterogeneous for intravenous administration.
Intravenous Vitamin C (PDQ®)–Health Professional VersionIntravenous vitamin C, with and without conventional cancer therapies, appeared promising in early studies and was well tolerated.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security